Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata

Barbulescu, Chauncey C.; Goldstein, Nathaniel B.; Roop, Dennis R.; Norris, David A.; Birlea, Stanca A.

doi:10.1016/j.jid.2019.03.1142

Cited by 26 publications

(21 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence for therapeutic efficacy of JAK-inhibitors or TYK2inhibitors has also been suggested in several other immunemediated inflammatory dermatoses, including atopic dermatitis, alopecia areata, vitiligo, 84 palmoplantar pustulosis and a case of a mucocutaneous disease called idiopathic erythema multiforme associated with a mutation in TRPS1 and JAK-STAT activation. 85 Taken together, PsO belongs to a group of chronic inflammatory skin diseases for which inhibition of JAKs or TYK2 has shown clinical efficacy.…”

Section: Dermatological Diseases Including Psomentioning

confidence: 99%

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

et al. 2020

View full text Add to dashboard Cite

ObjectivesJanus kinase inhibitors (JAKi) have been approved for use in various immune-mediated inflammatory diseases. With five agents licensed, it was timely to summarise the current understanding of JAKi use based on a systematic literature review (SLR) on efficacy and safety.MethodsExisting data were evaluated by a steering committee and subsequently reviewed by a 29 person expert committee leading to the formulation of a consensus statement that may assist the clinicians, patients and other stakeholders once the decision is made to commence a JAKi. The committee included patients, rheumatologists, a gastroenterologist, a haematologist, a dermatologist, an infectious disease specialist and a health professional. The SLR informed the Task Force on controlled and open clinical trials, registry data, phase 4 trials and meta-analyses. In addition, approval of new compounds by, and warnings from regulators that were issued after the end of the SLR search date were taken into consideration.ResultsThe Task Force agreed on and developed four general principles and a total of 26 points for consideration which were grouped into six areas addressing indications, treatment dose and comedication, contraindications, pretreatment screening and risks, laboratory and clinical follow-up examinations, and adverse events. Levels of evidence and strengths of recommendations were determined based on the SLR and levels of agreement were voted on for every point, reaching a range between 8.8 and 9.9 on a 10-point scale.ConclusionThe consensus provides an assessment of evidence for efficacy and safety of an important therapeutic class with guidance on issues of practical management.

show abstract

Section: Dermatological Diseases Including Psomentioning

confidence: 99%

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Therefore, PRP has recently attracted much attention, as its beneficial effects have already been used in dermatology for skin rejuvenation and acne scar treatments [ 33 ]. The bioactive substances contained in PRP not only inhibit the inflammation processes but stimulate the regenerative processes that are also necessary to restore the normal melanocyte function in the epidermis [ 34 ].…”

Section: Discussionmentioning

confidence: 99%

A Simple Drug Delivery System for Platelet-Derived Bioactive Molecules, to Improve Melanocyte Stimulation in Vitiligo Treatment

et al. 2020

View full text Add to dashboard Cite

Vitiligo is the most common depigmentation disorder of the skin. Currently, its therapy focuses on the halting of the immune response and stimulation of the regenerative processes, leading to the restoration of normal melanocyte function. Platelet-rich plasma (PRP) represents a safe and cheap regenerative therapy option, as it delivers a wide spectrum of native growth factors, cytokines and other bioactive molecules. The aim of this study was to develop a simple delivery system to prolong the effects of the bioactive molecules released from platelets. The surface of electrospun and centrifugally spun poly-ε-caprolactone (PCL) fibrous scaffolds was functionalized with various concentrations of platelets; the influence of the morphology of the scaffolds and the concentration of the released platelet-derived bioactive molecules on melanocytes, was then assessed. An almost two-fold increase in the amount of the released bioactive molecules was detected on the centrifugally spun vs. electrospun scaffolds, and a sustained 14-day release of the bioactive molecules was demonstrated. A strong concentration-dependent response of melanocyte to the bioactive molecules was observed; higher concentrations of bioactive molecules resulted in improved metabolic activity and proliferation of melanocytes. This simple system improves melanocyte viability, offers on-site preparation and is suitable for prolonged topical PRP administration.

show abstract

“…7 While these strategies are effective, alternative therapeutic interventions such as PRP offer a regenerative treatment approach, fostering a fertile environment rich in growth factors and cytokines to help promote and restore normal cellular function. 8 In addition to melanocytes, keratinocytes and fibroblasts as well as a multitude of inflammatory pathways are involved in vitiligo pathogenesis, and subsequent PRP stimulation of various factors may promote the differentiation, proliferation, and maturation of melanocytes and keratinocytes, leading to epidermal repigmentation. 5,6,8 Previous studies have found intradermal PRP injections to be an effective adjunctive therapy, when used concomitantly with light and laser therapies.…”

Section: Discussionmentioning

confidence: 99%

“…8 In addition to melanocytes, keratinocytes and fibroblasts as well as a multitude of inflammatory pathways are involved in vitiligo pathogenesis, and subsequent PRP stimulation of various factors may promote the differentiation, proliferation, and maturation of melanocytes and keratinocytes, leading to epidermal repigmentation. 5,6,8 Previous studies have found intradermal PRP injections to be an effective adjunctive therapy, when used concomitantly with light and laser therapies. An open-label split-body trial comparing NB-UVB alone to NB-UVB with PRP in 60 Egyptian patients with stable nonsegmental symmetric vitiligo demonstrated that 75% of patients in the NB-UVB with PRP group exhibited a good or excellent response after 4 months, whereas none of those in the NB-UVB-alone group exhibited similar response rates.…”

Section: Discussionmentioning

confidence: 99%

Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report

Yin¹,

Adotama²,

Svigos³

et al. 2020

JAAD Case Reports

View full text Add to dashboard Cite

Harnessing the Power of Regenerative Therapy for Vitiligo and Alopecia Areata

Cited by 26 publications

References 68 publications

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

A Simple Drug Delivery System for Platelet-Derived Bioactive Molecules, to Improve Melanocyte Stimulation in Vitiligo Treatment

Platelet-rich plasma, a promising adjunctive treatment for vitiligo: A case report

Contact Info

Product

Resources

About